Patrick Daly

DocwireNews

Sleep disruptions in patients with obstructive sleep apnea (OSA) can lead to excessive daytime sleepiness (EDS), which can persist despite adequate compliance with continuous positive airway pressure (CPAP) therapy. Researchers, led by Richard K. Bogan, MD, evaluated danavorexton, a small-molecule orexin-2 receptor (OX2R) agonist, for the adjunct treatment of EDS due to OSA.In their study, which was published in Sleep Medicine, they reported danavorexton improved objective and subjective sleep measures compared with placebo among patients with OSA and residual <a href="https://docwirenews.com/post/daytime-sleepiness-driving-ms">daytime sleepiness</a> despite CPAP use. They also noted danavorexton improved wakefulness in patients who did not have orexin deficiency.<h3>Danavorexton for Sleepiness in Patients With OSA&nbsp;</h3>The phase 1b <a href="https://clinicaltrials.gov/ct2/show/NCT05180890" target="_blank" rel="noopener">study</a> enrolled 25 patients aged 18 to 67 years with adequate CPAP use to receive 1 of 6 treatment schedules of single intravenous infusions of danavorexton 44 mg, danavorexton 112 mg, and placebo.A total of 23 patients completed all treatment periods. The primary end points were adverse events and maintenance of wakefulness test (MWT), Karolinska Sleepiness Scale (KSS), and the psychomotor vigilance test (PVT) scores.According to the authors, both the danavorexton 44 mg and 112 mg groups showed improvements in mean MWT, KSS, and PVT scores compared with the placebo group.Among the 25 patients, 16 (64.0%) experienced treatment-emergent adverse events (TEAEs), and 12 (48%) had TEAEs judged to be related to danavorexton treatment. Additionally, urinary TEAEs were reported in 3 patients in the danavorexton 44 mg group, 7 in the 112 mg group, and no patients in the placebo group. No TEAEs leading to discontinuation of treatment or death occurred.Overall, Dr. Bogan and colleagues supported that OX2R agonists can improve sleep-wake regulation and suggested &ldquo;danavorexton may be a useful adjunct therapy for patients experiencing daytime sleepiness as a result of OSA.&rdquo;Find More Content on <a href="https://docwirenews.com/page/sleep-disorders">Sleep Disorders and Neurology</a>

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

Danavorexton: Treating Excessive Daytime Sleepiness in OSA

Sleep Disorders

Danavorexton improved sleep measures in patients with OSA who had excessive daytime sleepiness despite adequate CPAP use.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe